Combining both types of agents may yield additional benefits: in a recent observational propensity-matched study from 3 US claims databases of 12,854 patients with type 2 diabetes who added an SGLT2i or sulfonylurea to baseline GLP-1 RA treatment, adding an SGLT2i produced greater cardiovascular benefit (comprising MI, stroke, all-cause mortality, and HHF) [17]
Targeting both receptors simultaneously, as with tirzepatide, leverages these complementary effects, enhancing insulin secretion [3], reducing appetite, improving insulin sensitivity, and supporting weight loss more effectively than single receptor agonists
However, because of their efficacy at reducing fever, treating inflammation, and minimizing thrombotic and cancer risk (Mills 2012), a complete cessation of NSAIDs, aspirin, or acetaminophen usage may not be suitable for everyone
Protocol de aplicare: diluai coninutul unei fiole n 1,5 l de ap i consumai-l n timpul zilei
Continental Hospitals supports access to modern medications like semaglutide and offers full medical guidance for safe usage
When GLP-1 and GIP agonism handle glucose regulation, the glucagon component can drive its metabolic benefits without the hyperglycemic risk